Allergies & Asthma

Researchers looking for post-breastfeeding dietary patterns in two prospective birth cohorts that predispose infants to asthma found one, and it wasn’t what anyone expected. After switching from breast milk, babies up to age 1 whose protein intake came largely from meat products — as opposed to dairy, fish, or egg proteins — showed more than
0 Comments
Several studies caught our eye at the just-concluded European Respiratory Society’s virtual annual meeting. Among them: more negative findings for ivermectin as a COVID-19 treatment; clinical performance of a novel image-analysis system that determines in real time whether lung tissue biopsies collected during surgery contain malignant cells; and insights into just how triple therapy for
0 Comments
Exercise capacity in patients with chronic obstructive pulmonary disease (COPD) increased substantially following a single IV iron infusion, a researcher reported. With patients’ tolerance for physical activity measured with two standard assessments — the 6-minute walk test (6MWT) and a constant work-rate exercise test — more than half the patients receiving the infusion achieved the
0 Comments
Here’s another likely health impact from climate change to add to the ever-growing list: more frequent chronic obstructive pulmonary disease (COPD) exacerbations. Each 1°C increment in outdoor temperature, after adjustment for humidity levels, was associated with a 2% increase in odds that COPD patients would experience exacerbations 2 days later (P=0.002), reported Supaksh Gupta, MD,
0 Comments
Managing your allergies can be costly — especially when your daily antihistamine isn’t cutting out all of your symptoms. With so many products that claim to reduce allergy symptoms, it can be difficult to know which are worth the investment. In this blog, read about three of the top allergy products that we find to
0 Comments
Most highly allergic adults were able to safely receive the two-dose series of the Pfizer/BioNTech COVID-19 vaccine (BNT162b2; Comirnaty), a prospective single-center study found. Of 429 highly allergic patients who received the first dose of the mRNA vaccine, mild allergic reactions occurred in 1.4% and 0.7% experienced anaphylaxis, reported Nancy Agmon-Levin, MD, of Sheba Medical
0 Comments
Questions about whether COVID symptoms are different with Delta compared with earlier variants have been raised again, after a Louisiana public health official recently said patients are presenting with more mild symptoms. Louisiana’s State Health Officer Joe Kanter, MD, MPH, told a local New Orleans radio station that many COVID patients are now developing symptoms
0 Comments
While a completely peanut-free environment is difficult to provide in an open baseball stadium where peanuts are sold and consumed by many of the fans, Major League Baseball (MLB) teams are reaching out to the baseball fans with peanut allergies by providing peanut controlled seating for selected games. Here is a comprehensive list of all
0 Comments
ZED1227, a potential therapeutic transglutaminase 2 inhibitor, reduced mucosal damage from gluten in celiac disease patients, a randomized proof-of-concept trial found. At week 6, the difference in villus height-to-crypt depth average ratio, a measurement of intestinal injury, was significant at three different dosages of ZED1227 (10 mg, 50 mg, and 100 mg) compared to placebo,
0 Comments
It’s all fun and games (and barbecues and boating) until your allergies kick in and put a pause on your Fourth of July celebrations. Whether you struggle with food or environmental allergies, there are steps you can take to help steer clear of reactions this holiday weekend. Avoid environmental triggers In early July, grass and
0 Comments
Note that some links may require registration or subscription. COVID deaths in Brazil surpassed 500,000, and protesters in more than 20 cities are blaming President Jair Bolsonaro for downplaying the pandemic. (NPR) The more contagious and possibly more deadly Delta variant will “probably” become the dominant strain in the U.S. in the next couple of
0 Comments
Among children with uncontrolled, moderate-to-severe asthma, treatment with the biologic dupilumab (Dupixent) was associated with a reduction in exacerbation and improvements in lung function in phase III findings from the international VOYAGE trial. Evidence of lung function improvement occurred within 2 weeks of treatment initiation, and was sustained during the 52-week randomized, placebo-controlled trial. Compared
0 Comments
A first-in-class drug under development for severe asthma passed what its developers hope is the final test: achieving its primary endpoint in a phase III registration trial dubbed NAVIGATOR and now reported in a major journal. Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), cut the annualized rate of asthma exacerbations by more than
0 Comments